facebook

For adults and children with hemophilia A

REACH HIGHER With the Long-lasting
Protection of AFSTYLA

AFSTYLA, with a twice-weekly dosing option, delivers long-lasting bleed protection using a novel single-chain Factor VIII design

Blue Ribbon

Twice-weekly dosing can mean fewer infusions each week. Ask your doctor if twice-weekly dosing is right for you.

Twice-weekly dosing helped David

FDA approved for dosing 2 to 3 times a week.

Learn about AFSTYLA dosing

2 times weekly

ZERO median annualized spontaneous bleeds* were reported in clinical trials for children and adults regardless of dosing schedule.

Cody turns to AFSTYLA for bleed protection

Zero bleeds (median AsBR*) regardless of age or dosing schedule in clinical trials.

Explore AFSTYLA protection

*AsBR=annualized spontaneous bleeding rate.

Zero bleeds (median AsBR*)

The safety of AFSTYLA was shown in 258 previously treated children, adolescents, and adults over 19,545 exposure days.

One of the largest FVIII clinical trial programs

Zero inhibitors in a clinical trial of 258 previously treated patients.

Formation of inhibitors to Factor VIII has been reported following use of AFSTYLA.

See AFSTYLA safety profile

Clinical trials

†Previously untreated patients may be at greater risk for development of inhibitors.

*AsBR=annualized spontaneous bleeding rate.

†Previously untreated patients may be at greater risk for development of inhibitors.

Get the latest from AFSTYLA

Sign up today.

Email address

Considering a change in your
hemophilia A treatment?

purple connector

Find out if AFSTYLA is right for you

Use these tools to help you decide.

CSL Behring makes it easy to start on AFSTYLA. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.

Call 1-800-676-4266 to get detailed information about the services available to you.

See how to switch

CSL Behring an established leader
in bleeding disorders

After more than 30 YEARS of experience in bleeding disorders, CSL Behring remains committed to developing innovative therapies for the people who need them

Join Us for a Free Interactive Event

Connect and learn more about living
with and managing hemophilia A

Register
You are now leaving the current website.

Do you want to continue?

No Yes